Published in Duluthian Magazine, March/April 2015
Clinical trials help advance cancer treatment at St. Luke’s Regional
Cancer Center
“It’s cancer.”
Few phrases in the English language have the stopping power of those two
words. In our society, it seems almost everyone has a story of a friend
or loved one who has had to deal with cancer in some form. According to
the National Cancer Institute, there are more than 100 different types
of cancer, originating in virtually every organ in the human body. In
the United States, there will be an estimated 1.6 million new cases of
cancer in 2015, 29,000 of which will occur in Minnesota. Dr. Basem Goueli,
MD, PhD, Medical Director of St. Luke’s Regional Cancer Center,
says that while those statistics are useful in providing a sense of the
impact of cancer, “we treat every patient uniquely, as cancer therapy
is highly nuanced, and every patient is different.”
The role of clinical trials
One of the most powerful tools that an oncologist has in the fight against
cancer is access to the newest experimental cancer drugs. These drugs
are rapidly being developed and tested through a multi-step process called
clinical trials, which are
stringently controlled, and designed to test the efficacy of new drugs on specific
types of cancer. “The idea behind a clinical trial is to see if
a drug will benefit patients,” said Dr. Goueli. “These drugs
can prove instrumental in a patient’s fight against cancer; they
can sometimes provide hope where there was none.”
The challenge, says Dr. Goueli, is convincing pharmaceutical companies
to allow your center to participate in their trials. “In order for
a cancer center to conduct a trial, it needs to have a strong research
staff, a clinical trial infrastructure, a significant patient population,
and an oncology team with a proven record that pharmaceutical companies
can trust. It takes an enormous amount of effort to ensure that all the
protocols are being met, and that requires a high level of organization
and competency.”
Size matters
There are thousands of clinical trials being conducted at major medical
centers throughout the country, but it is unusual for a health system
the size of St. Luke’s to have as robust a clinical trial program
as it does. St. Luke’s Regional Cancer Center has been able to bring
several of the most promising cancer therapeutics to northern Minnesota
because of its research department—Whiteside Institute for Clinical
Research—trial infrastructure, well-coordinated scientific and Institutional
Review Board processes, relationship with pharmaceutical companies and
talented Hematology and Oncology staff.
“We actually have an advantage over larger, health systems, because
our size enables us to more efficiently recruit and initiate clinical
trials in many ways,” said Dr. Goueli. “We are very selective
in the trials that we participate in, as we strive to recruit only the
most promising clinical trials based on our understanding of the mechanisms
of the drugs used, and the diseases they are being used to treat. Accordingly,
we currently have excellent clinical trials in leukemias, and in cancers
involving the breast, prostate, colon, brain, lung and ovary.”
The future of cancer care
Clinical trials have and will continue to play a central role in the treatment
of cancer patients. “I am very proud of the fact that we have the
most promising clinical trial base in northern Minnesota,” said
Dr. Goueli, “for we are constantly working with pharmaceutical companies
to bring the most exciting cancer therapies to our center for our patients,
as they deserve nothing less.”
In addition to clinical trials, St. Luke’s Regional Cancer Center
is also employing genomic and molecular profiling of tumors to treat cancer
patients. “We firmly believe that genomic and molecular profiling
allows us to create a more customized treatment plan for each individual
patient, and can provide us with additional attractive treatment options
for patients,” said Dr. Goueli. “We recognize that cancer
care is changing at a breakneck pace, and we are constantly evolving to
ensure that we are at the cutting edge of cancer treatment.”
Compassion and excellence
Effectively treating cancer is a balance of science and empathy. “At
St. Luke’s Regional Cancer Center we treat our patients as though
they are our fathers, mothers, brothers, sisters or children,” said
Dr. Goueli. “Our patients consistently get the best of our hearts
and the best of our minds, and that’s not rhetoric. Our patients
have a level of accessibility to their physician that is largely unprecedented,
and we are very proud of that fact.”
BELOW: Dr. Basem Goueli, Medical Director of St. Luke’s Regional
Cancer Center, talks with patient Taire Suliin in the Cancer Center’s
infusion therapy clinic